SOX5 and neurodevelopmental disorder: Whether the partial agonist properties of aripiprazole confer advantages in SOX5-related neurodevelopmental disorders remains unknown, but this case suggests that switching to an alternative agent with a different pharmacodynamic profile is a reasonable strategy when paradoxical reactions occur.